Most Recent
Zoetis hit with costs in bovine gene patent spat
Zoetis has been ordered to pay Scidera’s costs of defending an unsuccessful summary dismissal application on a lump sum basis in a dispute over a bovine gene patent, with a judge rejecting its “premature” bid for a set-off. 
CSIRO wins appeal over gut-friendly wheat patent
The CSIRO has successfully appealed a decision that blocked the government agency’s application to patent a method of producing high-fibre wheat.
Regeneron, Bayer settle appeal over launch of Sandoz’s Eylea biosimilar
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea. 
Judge ‘running out of patience’ in Scidera’s bovine gene patent suit
A judge has declined to order US-based animal genomics company Scidera to file a position statement in its bovine gene patent infringement suit and said she was “running out of patience” after unsuccessful strike-out and summary dismissal applications by the defendants.
Scidera’s bovine gene patent suit survives summary dismissal bid
Animal drug company Zoetis has lost its bid for summary dismissal of claims that it infringed US-based animal genomics company Scidera's bovine gene patent, with a judge saying its novel arguments were not so clear-cut and needed to be worked out at trial.
Regeneron, Bayer take fight over Eylea biosimilar to appeals court
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Regeneron, Bayer lose bid to block Sandoz from launching Eylea biosimilar
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
‘Further or in the alternative’ no problem in bovine gene patent suit: court
A group of Australia’s leading beef and dairy companies has failed to strike-out a suit alleging their genetic testing system for cattle infringes the patent of a US genomics company, with a judge rejecting objections to the phrase ‘further or in the alternative’.
Bayer launches High Court appeal to revive Xarelto patents
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
Bayer’s patents for blockbuster blood thinner Xarelto invalid: court
Bayer has lost its battle to protect top-selling blood thinner Xarelto from generic competition, with the Full Court finding two patents for the drug are invalid.